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Abstract 18 
Acromegaly in humans is usually sporadic, however up to 20% of familial isolated pituitary 19 
adenomas are caused by germline sequence variants of the aryl-hydrocarbon-receptor interacting 20 
protein (AIP) gene. Feline acromegaly has similarities to human acromegalic families with AIP 21 
mutations. The aim of this study was to sequence the feline AIP gene, identify sequence variants and 22 
compare the AIP gene sequence between feline acromegalic and control cats, and in acromegalic 23 
siblings. The feline AIP gene was amplified through PCR using whole-blood genomic DNA from 10 24 
acromegalic and 10 control cats, and three sibling pairs affected by acromegaly. PCR products were 25 
sequenced and compared to the published predicted feline AIP gene. A single non-synonymous SNP 26 
was identified in exon 1 (AIP:c.9T>G) of two acromegalic cats and none of the control cats, as well as 27 
both members of one sibling pair. The region of this SNP is considered essential for the interaction of 28 
the AIP protein with its receptor. This sequence variant has not previously been reported in humans. 29 
Two additional synonymous sequence variants were identified (AIP:c.481C>T and AIP:c.826C>T). This 30 
is the first molecular study to investigate a potential genetic cause of feline acromegaly and 31 
identified a non-synonymous AIP single nucleotide polymorphism in 20 % of the acromegalic cat 32 
population evaluated, as well as in one of the sibling pairs evaluated. 33 
 34 
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1. Introduction 37 
Feline acromegaly is an increasingly recognised endocrinopathy which is predominantly caused by a 38 
growth hormone producing adenoma in the anterior pituitary gland [1–3]. Chronic excessive growth 39 
hormone secretion results in increased insulin-like growth factor-1 (IGF-1), soft tissue and bone 40 
growth, increased risk of diabetes mellitus and cardiovascular disease.  41 
The majority of human pituitary adenomas that cause acromegaly are sporadic but some occur in a 42 
familial setting by genetic inheritance of disease causing gene sequence variants [4]. Familial causes 43 
of acromegaly include sequence variants within MEN1, protein kinase A regulatory subunit-1 alpha, 44 
GNAS1 and aryl hydrocarbon receptor interacting protein (AIP) genes [5]. Feline acromegaly is 45 
clinically most similar to human AIP-associated acromegaly demonstrating a male predominance, 46 
macroadenomas and poor biochemical response to octreotide or lanreotide therapy [1,3,6–9]. 47 
Genomic variants of the AIP gene account for 20 % of human familial isolated pituitary adenomas 48 
(FIPA), of which 30 % are functional somatrophinomas. Disease onset is typically at a younger age in 49 
AIP gene variant human acromegalics compared to other causes of acromegaly [10]. AIP-variant 50 
acromegaly has also been identified in patients with non-familial human acromegaly [11,12]. 51 
The human AIP gene is located on chromosome 11q13 and containing six exons which encode for a 52 
330 amino acid protein. The AIP protein is thought to act as a tumour suppressor by mediating gene 53 
transcription via interaction with the aryl-hydrocarbon receptor (AhR), and modulates oestrogen and 54 
androgen receptors and response to xenobiotics[13–15]. The latter is of extra interest since cats 55 
with acromegaly demonstrate increased circulating concentrations of organohalogenated 56 
contaminants [16]. The tertiary structure of the C-terminal region of the AIP protein is a 57 
tetratricopeptide double helix motif and a terminal seven amino acid helix known as the TPR domain 58 
[17]. Sequence variants within the TPR domain may affect the binding properties of the AIP protein 59 
and the importance of this region is highlighted by the finding that 70% of clinically relevant genomic 60 
sequence variants in humans occur within this region [13].  61 
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This aim of the study was to sequence the feline AIP gene, identify any genomic sequence variants 62 
and compare germline AIP sequences of acromegalic cats and controls, as well as affected siblings.  63 
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2. Materials and methods 64 
2.1 Animals 65 
This study was approved by the Ethics and Welfare Committee at the Royal Veterinary College (RVC), 66 
ethical approval number URN 2014 1306.  67 
Medical records of client owned cats who presented to the RVC Acromegalic Cat Clinic from first 68 
opinion veterinary practices between 2005 to 2013 were searched for cats with a diagnosis of 69 
acromegaly (inclusion criteria were serum IGF-1 > 1000 ng/mL and pituitary mass identified using 70 
contrast-enhanced pituitary computed tomography or at necropsy). Total serum IGF-1 was 71 
measured by a commercially available radioimmunoassay previously validated for cats (Nationwide 72 
Laboratories, Cambridge, UK) [3]. The intra- and inter-assay coefficient of variation (CV) has 73 
previously been reported: inter-assay CV 4.6 % for a cat sample of 519 ng/mL; 9.3 % for a standard 74 
sample of 216 ng/mL; 12.1 % for a standard sample of 62 ng/mL; intra-assay CV 7.9 % for a cat 75 
sample of 172 ng/mL run 18 times [3]. All cats had whole blood stored in EDTA anticoagulant from 76 
residual clinical samples frozen at -80 
o
C. The youngest ten cats were selected in an attempt to 77 
increase chances of detecting a feline AIP-variant (AIP-variant associated acromegaly in people 78 
typically affects humans at a younger age than non AIP-variant associated acromegaly). Control cats 79 
were selected from the RVC Genetic Archive using residual whole blood samples stored in EDTA anti-80 
coagulant from cats who were presented to RVC as a referral patient from first opinion veterinary 81 
practices. All control cats were considered unlikely to have acromegaly on the basis of no history or 82 
clinical signs suggestive of acromegaly and were greater than 15 yr of age. This older age was chosen 83 
to minimise the chances of including cats that could have developed acromegaly at a later age. 84 
Residual whole blood samples stored in EDTA anti-coagulant from sibling pairs of cats, all diagnosed 85 
with acromegaly using the criteria above, were recruited and analysed. This was a further attempt to 86 
increase the chances of detecting AIP-variants (should they exist) because AIP-variant associated 87 
acromegaly is most commonly encountered in a familial setting. 88 
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 89 
2.2 Identification of the feline AIP gene sequence 90 
The feline genome was searched for nucleotide similarity to the coding sequence of the human AIP 91 
gene using a BLAST search and Felis catus (domestic cat) nucleotide database 92 
(https://blast.ncbi.nlm.nih.gov). This revealed a six exon, 1250 base pair sequence located on 93 
chromosome D1 (NCBI Reference Sequence: NW_004065058.1, Assembly Felis_catus_6.2). Primers 94 
for cDNA were designed using Primer3Plus (http://www.primer3plus.com) and NCBI PrimerBLAST 95 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) for DNA polymerase. The nucleotide sequence of 96 
the sense primer was 5’-3’ TAG AAG TTG CCG AAG CAG GT and anti-sense primer was 5’-3’ GGG AGA 97 
GAT AAA TAC GGC CTT T. Polymerase chain reactions (PCRs) were performed using 1 µL of cDNA 98 
derived from the pituitary of an acromegalic cat (tissue obtained during necropsy), 13 µL of water, 5 99 
µL of 5xHispec
 
(Bioline, London, UK), 2.5 µL of PCR buffer (Roche, Welwyn Garden City, UK), 1.25 µL 100 
of MgCl2 (5 nM) (Bioline, London, UK), 0.25 µL of 250 μM dNTPs (Bioline, London, UK), 1 µL of each 101 
sense and anti-sense primer (each at 200 pmol/µL) and 0.1 µL of Immolase (Bioline, London, UK). 102 
PCR amplification cycles (n = 35) were performed using PCR thermal cycler (G-Storm GS1 thermal 103 
cycler, Somerton, UK) 
 
according to the following protocol: denaturation at 95 
o
C for 10 min followed 104 
by 94 
 o
C for 40 s, annealing at 55 
o
C for 30 s, followed by elongation at 72 
o
C for 2 min. The final 105 
cycle was followed by a final elongation step at 72 
o
C for 10 min. Agarose gel electrophoresis was 106 
performed for 30 min followed by visualisation using 590 nm UV light then DNA purification using a 107 
commercially available kit (GenElute Gel Extraction Kit, Sigma-Aldrich. Dorset, UK). The extracted 108 
DNA was submitted for standard Sanger sequencing (Source BioScience LifeSciences, Nottingham, 109 
UK) and compared to the reference feline sequence using sequence analysis software (CLC Main 110 
Workbench 7, Qiagen Aarhus, Waltham, MA, USA). 111 
  112 
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2.3 SNP discovery and assessment of siblings 113 
Once the complete coding sequence of the feline AIP gene was identified, whole blood origin 114 
genomic DNA from case and control samples, and feline acromegalic siblings, was extracted from 115 
whole blood stored in EDTA anticoagulant using a commercially available DNA extraction kit
 
(DNeasy 116 
blood and tissue kit, QUIAGEN, Manchester, UK) according the manufacturer’s instructions. Sense 117 
and anti-sense gDNA specific primers were designed to amplify exons 1, 2, 3 and 4 to 6. The 118 
optimum primer set and PCR conditions were determined for each primer pair (Table 1).  119 
Amplicon gel electrophoresis, gel excision and purification were performed using the same protocol 120 
as for AIP cDNA identification. Standard Sanger sequencing was performed to determine the exon 121 
sequences. Amplicons were compared to the reference feline genome and to each other using 122 
commercially available gene analysis software (CLC Main Workbench 7, Qiagen Aarhus, Waltham, 123 
MA, USA).  124 
 125 
2.4 Structural effect assessment 126 
The structural and functional effect of the identified non-synonymous SNP was estimated using 127 
protein modelling software (Pyhre2 version 2.0 [18], PyMOL Molecular Graphics System Version 128 
1.7.4.4 Schrödinger LLC, Sorting Tolerant from Intolerant [SIFT] 129 
[http://sift.jcvi.org/www/SIFT_seq_submit2.html] and Polyphen-2 130 
[http://genetics.bwh.harvard.edu/pph2/] programmes).  131 
 132 
2.5 Statistics 133 
Statistical analysis was performed using Windows Excel 2010 and SPSS (IBM Statistics SPSS 21). 134 
Statistical significance was established using P < 0.05. Normality testing was performed visually using 135 
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histograms and Shapiro-Wilk tests. Groups were compared using the Student’s t test where 136 
appropriate and Fisher’s exact test was used to compare SNP frequency between groups. 137 
 138 
3 Results 139 
3.1 Animals 140 
The mean age of control cats (19.2 ± 2.4 yr) was greater than acromegalic cats (10.7 ± 2.7 yr; P < 141 
0.001). There were eight domestic short hair (DSH) cats, one British short hair and one Maine Coon 142 
cat in the acromegalic group and nine DSH and one domestic long hair cat in the control group. 143 
There were six male and four female cats in the acromegalic group and three male and seven female 144 
cats in the control group. 145 
Genomic DNA of three pairs of sibling cats (all with a diagnosis of acromegaly) was acquired; all were 146 
DSH with a median age of 11 yr (range 9 to 12), four were male and two were female, all were 147 
neutered. These siblings had a mean serum IGF-1 of 1640 ng/mL (range 1460 to 2000). 148 
 149 
3.2 Feline AIP coding sequence identification 150 
A single amplicon was identified using the pituitary cDNA template and primers designed for sense 151 
and anti-sense AIP primers. Sanger sequencing of an acromegalic case revealed an 1181 base pair 152 
amplicon, coding for a 330 amino acid protein. The coding sequence identified from the amplicon 153 
shared 100 % homology to the predicted mRNA transcript variant X1 of feline AIP gene 154 
(XM_003993700.2, Assembly: GCF_000181335.2). The feline AIP nucleotide and predicted amino 155 
acid sequences were compared to the human AIP nucleotide and amino acid sequences and were 156 
found to be 91 % and 96 % homologous, respectively (Figure 1). 157 
 158 
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3.3 SNP discovery and assessment of acromegalic siblings 159 
Two female DSH cats in the acromegalic group had a heterozygote non-synonymous SNP in exon 1, 160 
position 9 of the coding sequence (AIP:c.9T>G) changing the third amino acid from aspartic acid to 161 
glutamic acid (Figure 2). Two additional heterozygote synonymous SNPs were identified; 162 
AIP:c.481C>T in exon 4 of two female DSH cats in the control group and AIP:c.826C>T in exon 6 of 163 
one male DSH cat in the acromegalic and one female DSH cat in the control group. The AIP:c.481C>T 164 
SNP has previously been reported in cats (rs783758897, http://www.ncbi.nlm.nih.gov/snp). 165 
The results of 3-D protein modelling predicted that the AIP:c.9T>G SNP resulted in a minor effect on 166 
the tertiary structure of the protein at the N-terminal. The SIFT score was 0.00, indicating the amino 167 
acid change could affect the protein function (scores > 0.05 are not predicted to have deleterious 168 
effects). Nevertheless, the prediction was deemed to be of low confidence. ThePolyPhen-2 report 169 
described the predicted mutation to be benign with a score of 0.003 (sensitivity 0.98 and specificity 170 
0.44). 171 
The AIP:c.9T>G SNP was also identified in one pair of acromegalic siblings (both male cats) and these 172 
two cats also had the AIP:c.481C>T SNP. No additional SNPs were identified among the other two 173 
pairs of siblings. 174 
 175 
4 Discussion 176 
The feline AIP-gene was sequenced and showed homology with the human equivalent. The 177 
sequencing results revealed three SNPs in the coding sequence of the AIP gene. A non-synonymous 178 
SNP was not detected in the control cats, whereas two of the ten initially assessed acromegalic cats 179 
displayed a non-synonymous SNP in exon 1 (AIP:c.9T>G). This SNP was predicted to result in a minor 180 
structural change, suggesting a potential relevance, and was also detected in both members of one 181 
of the three subsequently assessed sibling pairs.  182 
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The majority of functionally important AIP SNPs identified in humans affect the C-terminus of the 183 
protein [19]. This region is essential for the binding of AIP to the AhR, which is thought to be 184 
required for tumour suppressor activity [20]. The only non-synonymous nucleotide variant that was 185 
identified in this study affects the N-terminal region. The AIP:c.9T>G SNP encodes for an amino acid 186 
change from aspartic acid to glutamic acid. The likely structural effect of the aspartic acid to glutamic 187 
acid was estimated to be minor. Nevertheless, minor changes may affect spatial preferences and 188 
amino acid interactions [21,22]. The AIP N-terminal is important because it is required for the 189 
stability of the AIP-AhR-receptor complex and essential for the regulation of the intracellular 190 
localization AhR [23]. It is possible that the described amino acid change could affect AIP interaction 191 
with the AhR and downstream tumour suppressor activity, even if it causes a minor structural 192 
change to the protein. AIP-variant associated acromegaly is most commonly identified in a familial 193 
setting in human medicine [7], which explains our additional interest in assessing acromegalic sibling 194 
cats. Recruitment of this subset of cats was difficult, resulting in a low number of siblings assessed. 195 
Nevertheless, one of the three assessed siblings pairs had the AIP:c.9T>G SNP.  196 
The AIP:c.9T>G SNP was heterozygous in all cats. The expected heterozygosity in an individual 197 
human genome estimates a SNP will occur once every 300 nucleotides and one study describing 198 
SNPs within the feline genome reported a SNP rate around one every 500 nucleotides [24–27]. 199 
Additionally, only 20 to 30% of heterozygous SNPs are estimated to affect protein function [28–30]. 200 
The identified AIP:c.9T>G SNP may not be clinically significant. Further functional studies would be 201 
beneficial to determine the significance of a change of the third amino acid from glutamine acid to 202 
aspartic acid. Additionally it is possible that homozygosity proves lethal or is associated with more 203 
severe disease leading to premature death, thus precluding eventual development of acromegaly 204 
later in life.  205 
The clinical records of all four of the AIP:c.9T>G variant cats (two cats from the original study and 206 
both members of one pair of sibling cats) revealed these cats had the following pituitary tumour 207 
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sizes (dorsoventral height): 8.3 mm, 8.4 mm, 4.6 mm, 16 mm. The median pituitary adenoma height 208 
of the largest reported group of acromegalic cats (n=68) was 6.1 mm (interquartile range 5.2 to 7.6, 209 
range 4.2 to 16) [31].Therefore three of the four cats had a pituitary height in the upper quartile of 210 
reported pituitary heights in acromegalic cats. Human AIP-variant-associated pituitary adenomas are 211 
frequently also larger adenomas than those not associated with AIP-variant. This study raises the 212 
possibility that, like in humans, the identified feline AIP-variant may also be associated with a more 213 
expansive behaviour of the tumour, though more cases need to be assessed to ascertain. 214 
Acromegaly in humans due to a germline AIP mutation develops at a younger age compared to the 215 
general population of acromegalics [32]. Ten young acromegalic cats were purposely selected for 216 
this study in order to maximise the chances of identifying a feline AIP-variant acromegalic 217 
population. In doing so, however, we might have biased our investigations, should no such 218 
correlation between age and this type of acromegaly exist in the cat, or should an opposite 219 
correlation exist.  220 
One of the limitations of the study is the small number of patients in each group. Preferentially we 221 
would have larger case and control numbers. This study was designed as a preliminary investigation 222 
of the feline AIP gene and its possible association with acromegaly in cats. The results imply an 223 
extension of this study would be worthwhile.  224 
In conclusion, we have identified a single non conservative SNP in exon 1 in 4 / 16 acromegalic cats 225 
investigated. This SNP has not been previously identified in human acromegalics. The SNP affects a 226 
region of the protein which might impact AIP protein function predisposing to acromegaly in 227 
affected cats. Larger screening studies, as well as functional studies would be required to assess this 228 
possibility further. 229 
 230 
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Appendix 349 
Table 1:  350 
Exon Primers Amplicon Denaturation Annealing 
35 cycles 
Elongation 
1 For 5’-3’ TAG AAG TTG CCG AAG CAG GT 
431 bp 
95
 O
C 
10 min  
94
 O
C 
40 s 
55
 O
C 
2 min 
72
 O
C 
2 min Rev 5’-3’ CCC TGC AAC GTT CTT ACG AT 
2 For 5’-3’ GGG TAA AGG TCA GGT GGT GA 369 bp 
 
95
 O
C 
10 min 
94
 O
C 
40 s 
64 
O
C 
2 min 
72
 O
C 
2 min Rev 5’-3’ GAT GGG GAA TAG GGG ATG AC 
3 For 5’-3’ GAG GAC TCC TGA GGG AAA GG 
400 bp 
95
 O
C 
10 min 
94
 O
C 
40 s 
64
 O
C 
2 min 
72
 O
C 
2 min Rev 5’-3’ GGT TTG GTG AGG CAC CTG 
4 For 5’-3’ CAG GGG TGT TGG TAG GAG AA 
1348 bp 
95
 O
C 
10 min 
94
 O
C 
40 s 
64
 O
C 
2 min 
72
 O
C 
2 min 
5 For 5’-3’ CAG CTC TCA GCG TCT CCT G 
220 bp 
95
 O
C 
10 min 
94
 O
C 
40 s 
64
 O
C 
2 min 
72
 O
C 
2 min Rev 5’-3’ GGT CAG AGG CCC AGT TGT G 
6 Rev 5’-3’ GGG AGA GAT AAA TAC GGC CTT T 
1348 bp 
95
 O
C 
10 min 
94
 O
C 
40 s 
64
 O
C 
2 min 
72
 O
C 
2 min 
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Figure 1:  352 
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Tables and Figures List: 358 
Table 1: PCR primers and conditions for genomic AIP gene amplification 359 
 360 
Figure 1: Comparison of the homology of the human and feline AIP amino acid sequence using 361 
CLUSTAL multiple sequence alignment by MUSCLE (3.8) (http://www.ebi.ac.uk/Tools/msa/muscle). 362 
The feline AIP protein was 96% homologous to the human AIP protein. 363 
 364 
Figure 2: Sanger sequencing chromatographs from three cats. The nucleotides shown represent the 365 
first 16 nucleotides of exon 1 of the feline AIP gene. The top two chromatographs contain the 366 
AIP:c.9T>G SNP (highlighted by red arrows) and the third chromatograph is the wild type (WT) feline 367 
AIP sequence. The AIP:c.9T>G SNP is heterozygous at nucleotide 9 and labelled K as denoted by the 368 
IUPAC nucleotide ambiguity code nomenclature.  369 
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Feline hypersomatotropism and acromegaly tumorigenesis: A potential role for the AIP gene 
 
• A non-synonymous heterozygous germline variant of the AIP gene (AIP:c.9T>G) was only 
found acromegalic cats 
• The AIP:c.9T>G variant encodes for an amino acid change from aspartic acid to glutamic acid 
in a region of the AIP protein considered to be important for its tumour suppressor activity 
• The AIP:c.9T>G variant may predispose to pituitary macroadenomas. Three of the four cats 
having this variant had pituitary tumours in the upper quartile of reported pituitary heights 
in acromegalic cats, as measured using contrast-enhanced computed tomography. 
